10-K: Modular Medical, Inc. Secures FDA Clearance for MODD1 Insulin Pump, Eyes Q3 2025 Launch Amidst Going Concern Doubts

Modular Medical, Inc., a pre-revenue medical device company, has received FDA clearance for its MODD1 insulin pump and plans initial shipments by September 2025, while acknowledging substantial doubt about its ability to continue as a going concern without further capital.

Summary

• Modular Medical, Inc. is a pre-revenue medical device company focused on developing innovative insulin pumps using modernized technology.
• The company's initial product, the MODD1 insulin pump, received FDA 510(k) clearance in September 2024 and is expected to commence initial shipments during the quarter ending September 30, 2025.
• A successor product, the Pivot, a tubeless patch pump, is planned for FDA 510(k) submission by October 31, 2025, with regulatory clearance and launch anticipated during the three months ending March 31, 2026.
• The company aims to expand the wearable insulin delivery device market by offering affordable, easy-to-use pumps designed for 'Almost Pumpers' – individuals deterred by the complexity and cost of existing devices.
• As of March 31, 2025, the company reported a net loss of $18.8 million for the fiscal year, compared to $17.5 million in fiscal 2024, and an accumulated deficit of $84.8 million.
• Cash and cash equivalents stood at $13.1 million as of March 31, 2025, following recent capital raises totaling approximately $18.7 million in net proceeds during fiscal 2025.
• Despite recent financing, management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months without raising additional capital.

Sentiment

Score: 3

Explanation: The company has achieved significant operational milestones, including FDA clearance for its initial product and a clear roadmap for future innovations, which are positive. However, the explicit 'going concern' warning, pre-revenue status, and continuous reliance on external financing for survival introduce substantial financial risk and uncertainty, heavily weighing down the overall sentiment.

Positives

• Received FDA 510(k) clearance for the MODD1 insulin pump in September 2024, a significant regulatory milestone.
• Plans to commence initial shipments of the MODD1 pump during the quarter ending September 30, 2025.
• Developing a next-generation tubeless patch pump, Pivot, with planned FDA submission by October 31, 2025, and expected clearance by March 31, 2026, offering cost and usability improvements.
• Aims to obtain CE mark clearance for both MODD1 and Pivot in the first quarter of 2026, opening European markets.
• Proprietary technology designed for mass manufacturing, potentially leading to 50% lower cost of goods than closest patch pump competitors.
• MODD1 pump is smaller and lighter than Insulet's Omnipod (20 grams empty vs. 26 grams, 23 grams filled vs. 28 grams) yet holds 50% more insulin (3mL vs. 2mL), addressing a significant market segment.
• Partnership with Phillips Medisize, a tier-one medical device manufacturer, for scalable production.
• Identified a large addressable market of 'Almost Pumpers' (estimated $3 billion opportunity) by focusing on ease of use, affordability, accessibility, and support.
• Strong intellectual property portfolio with 5 U.S. utility patents, 2 foreign patents, and 20 pending applications.
• Recent capital raises in November 2024 ($7.3 million net) and March 2025 ($11.4 million net) have bolstered cash reserves to $13.1 million.

Negatives

• Pre-revenue company with a history of significant operating losses, incurring net losses of $18.8 million in fiscal 2025 and $17.5 million in fiscal 2024.
• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months without raising additional capital.
• Requires substantial additional funding to complete development, expand manufacturing, and commercialize products, which may not be available on acceptable terms and could lead to significant stockholder dilution.
• Limited operating history and historical financial information make performance evaluation challenging.
• Highly competitive diabetes treatment market with larger, more established competitors (Medtronic, Tandem, Insulet).
• Reliance on third-party manufacturers and suppliers makes the company vulnerable to quality control issues, supply shortages, and price increases.
• Current insulin pump product (MODD1) does not yet have reimbursement or approved insurance coverage, which is critical for generating significant revenue.
• Subject to potential product liability and other claims, which could materially impact business and financial condition.
• Technological breakthroughs by competitors could render products obsolete.
• Significant concentration of beneficial ownership (executive officers, directors, and affiliates own approximately 14% of common stock), potentially limiting influence of other stockholders.

Risks

• The company might not be able to continue as a going concern due to significant operating losses and insufficient cash to fund operations for the next 12 months.
• The company is a pre-revenue medical device company with a history of significant operating losses and may never achieve or maintain profitability.
• Substantial additional funding is required to complete subsequent phases of product development and operations, and such funding may not be available or may substantially dilute existing stockholders.
• The company has a limited operating history and historical financial information, making performance evaluation difficult.
• Future cash requirements may differ significantly from current estimates, potentially adversely affecting operations and financial condition.
• The company may not be able to utilize a significant portion of its net operating losses and tax credits due to ownership changes.
• Technological breakthroughs in diabetes monitoring, treatment, or prevention could render the company's insulin pump products obsolete.
• Failure to attract and retain skilled directors, executives, employees, and consultants could impair product development and commercialization activities.
• Reliance on third parties for development, manufacturing, sales, marketing, and regulatory submissions poses risks if these parties fail to perform as expected.
• Inability to identify, negotiate, and maintain strategic alliances necessary to develop and commercialize products and technologies.
• Failure to receive necessary regulatory clearance or approvals for insulin pump products (e.g., Pivot, CE mark) could harm operations and commercialization.
• Competitors may develop products that are more effective, safer, or less expensive, impacting the company's market position.
• Inability to successfully scale-up manufacturing of products in sufficient quality and quantity could delay or prevent commercialization.
• Dependence on third-party suppliers for components makes the company vulnerable to supply shortages and price increases.
• Potential product liability and other claims could materially impact the business and financial condition.
• Legislative, regulatory, or medical cost reimbursement changes, including healthcare reform and drug-pricing reform laws, may adversely impact the business.
• Extensive regulation by the FDA could restrict sales and marketing and cause significant costs.
• Clinical testing results may not demonstrate the safety and efficacy of the device or may be insufficient for regulatory approval.
• Inability to obtain and maintain intellectual property protection relating to insulin pump products and research technologies.
• Risk of costly and time-consuming lawsuits for infringing on third-party intellectual property rights, with potential for unfavorable outcomes.
• Inability to protect the confidentiality of proprietary information could adversely affect the value of technology and products.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Failure to comply with FDA's quality system regulations by the company or contract manufacturers could interrupt manufacturing and distribution.
• Disputes with present or future contract partners over intellectual property ownership or other matters.
• Insulin pump products will be subject to recalls, harming reputation, business operations, and financial results.
• Current insulin pump product does not yet have reimbursement or approved insurance coverage, which is critical for generating significant revenue.
• Disruption and/or instability in economic conditions and capital markets could adversely affect the ability to access capital.
• International trade policies, including protectionist trade policies, such as tariffs and sanctions, could adversely affect the business.
• Third parties might attempt to gain unauthorized access to the company's network or seek to compromise its products, leading to data loss, reputational harm, and legal claims.
• Inability to satisfy Nasdaq continued listing requirements could lead to delisting, adversely affecting stock price and liquidity.
• Concentrated beneficial ownership may prevent other stockholders from influencing significant corporate decisions.
• Future sales of securities could adversely affect the market price of common stock and dilute investments.
• The board of directors can adopt recapitalizations through forward or reverse splits without stockholder approval.
• Failure to establish and maintain an effective system of internal controls could affect financial reporting accuracy or prevent fraud.
• Sustained inflation could have a material adverse effect on the business, financial condition, results of operations, and liquidity.

Future Outlook

Modular Medical, Inc. expects to continue evolving its MODD1 pump and its capabilities, with future Pivot products aiming to add phone-based control, Alternative Controller Enabled (ACE), and Automated Insulin Delivery (AID) capabilities for integration with popular continuous glucose monitors. The company envisions moving to a drug prefill model for cartridges and developing full-featured, multi-chamber pumps optimized for high time-in-range fully autonomous closed-loop insulin delivery, realizing true artificial pancreas systems. They also plan to expand into other applications beyond diabetes, such as weight loss, fertility, and simplifying the delivery of complex multi-drug cocktails, leveraging their multi-chamber pumping solutions.

Management Comments

• "We are actively working to manufacture and commercialize our MODD1 product and commence initial shipments during the quarter ending September 30, 2025."
• "We believe we will submit the notification for the Pivot by October 31, 2025, and we believe we could obtain regulatory clearance to market and launch Pivot during the three months ending March 31, 2026."
• "Our goal is to become the leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not just care for the super users, but diabetes care for the rest of us."
• "We believe that Phillips Medisize will be able to rapidly scale our production to higher volumes at lower cost."
• "We believe the present pump marketplace is approximately a $1.9 billion market, comprising 33% of T1D pumpers and a small group of T2D pumpers. Seagrove surveyed clinicians, and, in its 2021 report, estimated that 28% of T1D patients and 25% of T2D patients would adopt technology that was easier to use, learn and access and eligible for insurance reimbursement. We believe this represents a total addressable market of approximately $3 billion for us, assuming cartridge revenue of approximately $4,100 per patient, per year."
• "We believe that the insulin pump market is ready for a similar transition as that experienced in the CGM space. Our MODD1 pump represents a new and better offering to assist and induce a wide variety of patients to make the transition and overcome the objections to superior control by becoming a pumper."
• "Based on our current operating plan, substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included in Item 8 of this Report are issued exists."

Industry Context

The diabetes treatment market is experiencing a significant shift, with increasing interest in technology and wearables like Continuous Glucose Monitoring (CGM) devices. Modular Medical aims to capitalize on this trend by offering a simpler, more affordable insulin pump (MODD1 and future Pivot) to a large underserved segment, referred to as 'Almost Pumpers,' who are deterred by the complexity and high cost of existing pumps. The industry is moving towards more integrated and autonomous solutions, and the company's focus on ease of use and cost-effectiveness positions it to potentially expand pump adoption beyond the current 'super users' to a mass market, similar to the expansion seen in the CGM market with products like Freestyle Libre. The increasing move towards pharmacy benefits manager (PBM) models for patch pump reimbursement also simplifies onboarding, aiding market entry.

Comparison to Industry Standards

• Modular Medical's MODD1 pump is designed to address shortcomings of existing pumps, including complexity, cumbersomeness, high cost, and outdated style, which currently limit adoption by a substantial number of insulin-requiring individuals.
• Compared to the leading patch pump, Insulet's Omnipod, MODD1 is smaller (20 grams empty vs. 26 grams, 23 grams filled vs. 28 grams) and holds 50% more insulin (3mL vs. 2mL), which is significant as 24% of Type 1 and over 50% of the rapidly growing Type 2 patients require more than 2mL every three days.
• Unlike existing patch pumps, the MODD1 can be removed from the needle and replaced, avoiding insulin loss due to accidental dislodging, an issue for other patch pumps with which users have expressed considerable dissatisfaction.
• The MODD1's reusable pumping system is expected to provide a significant cost advantage over competitors like Insulet's Omnipod, which discards all electronics every three days, creating a higher cost architecture and significant waste.
• While traditional pumps like Medtronic's Minimed 770G/780G and Tandem's t:slim X2 are durable and receive high reimbursement (exceeding $4,000), they are often cumbersome with long tubing and integrated controllers, requiring extensive training (average pump user must go through 42 steps of setup and refill process every 72 hours) and daily management (2-4 hours per day).
• Modular Medical's product only requires nine steps for setup and refill every 72 hours, significantly simplifying the user experience compared to the average pump user's 42 steps.
• The company's strategy targets the 68% of T1D individuals and virtually all T2D individuals who rely on Multiple Daily Injection (MDI) therapy, a segment largely underserved by current complex pump offerings.
• The Pivot pump, Modular Medical's successor product, aims to be the only 3-milliliter, tubeless removable patch pump on the market, differentiating it from current tubeless options like Omnipod (2mL) and fixed basal rate pumps like Mannkind V-Go.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceeding that is believed to be likely to have a material adverse effect on its consolidated financial position or results of operations.
• No federal, state, or local governmental agency is presently contemplating any proceeding against the company.

Related Party Transactions

• Manchester Management Company, LLC (MMC), as the general partner of Manchester Explorer, L.P. (Explorer), combined with the holdings of its affiliates (JEB Partners LP, James Besser, Morgan Frank), owned approximately 9% of the company's outstanding common stock as of March 31, 2025.
• James Besser, the company's Chief Executive Officer, is a managing member of MMC.
• Morgan Frank, a member of the company's Board of Directors, serves as the portfolio manager of Explorer and as a managing member of MMC.
• Explorer purchased 900,000 shares in the February 2024 public offering for aggregate gross proceeds of $990,000.
• Explorer purchased 166,666 shares in the November 2024 public offering for aggregate gross proceeds of $250,000.
• Explorer purchased 260,416 units in the March 2025 private placement for aggregate gross proceeds of $500,000.
• James Besser purchased 78,125 units in the March 2025 private placement for aggregate gross proceeds of approximately $150,000.
• Two other members of the board of directors purchased a total of 35,937 units in the March 2025 private placement for gross proceeds of $69,000.
• The daughter of an executive officer is an employee of the company and was paid approximately $169,000 in fiscal 2025 and $137,000 in fiscal 2024, which includes the aggregate grant date fair values of stock options granted.

Stakeholder Impact

• Shareholders face potential significant dilution from future capital raises and the risk of losing most or all of their investment if the company cannot continue as a viable entity due to the 'going concern' warning. However, there is potential for long-term value creation if products gain market acceptance and profitability is achieved.
• Employees' continued employment and potential for equity-based compensation are tied to the company's success, but they face the risk of job loss if operations are curtailed due to insufficient funding.
• Customers (patients) stand to benefit from potential access to a simpler, more affordable insulin pump, which could improve diabetes management and overall quality of life, especially for those currently deterred by existing complex solutions.
• Suppliers and creditors face the risk of delayed or non-payment if the company encounters severe liquidity issues, but also the opportunity for increased business if manufacturing scales successfully and commercialization progresses.
• Regulatory authorities (FDA, SEC) will continue to oversee the company's compliance with medical device development, manufacturing, and financial reporting regulations, ensuring product safety and market integrity.

Next Steps

• Manufacture and commercialize the MODD1 product.
• Commence initial shipments of MODD1 during the quarter ending September 30, 2025.
• Prepare and submit a 510(k) premarket notification application to the FDA for the Pivot pump by October 31, 2025.
• Obtain regulatory clearance to market and launch Pivot during the three months ending March 31, 2026.
• Obtain Conformite Europeenne (CE) mark clearance for both MODD1 and Pivot products in the first quarter of 2026.
• Transfer manufacturing equipment and processes to Phillips Medisize.
• Hire and retain appropriate sales and marketing personnel to develop, implement, and launch promotional campaigns.
• Continue to evolve MODD1 pump capabilities and functionality in response to patient needs and platform roadmap.
• Seek to add phone-based control, Alternative Controller Enabled (ACE), and Automated Insulin Delivery (AID) capability to future Pivot products for integration with popular continuous glucose monitors.
• Develop full-featured, multi-chamber pumps optimized for high time-in-range fully autonomous closed-loop insulin delivery.
• Explore moving to a drug prefill model for cartridges.
• Seek additional financing through public or private equity offerings, debt financings, or strategic alliances.
• Conduct clinical studies specifically focused on improved adherence, more bolus deliveries per day, and providing clinicians with clear data on patient use.

Key Dates

Recommendation

Keywords

Insulin Pump, Diabetes Treatment, Medical Device, FDA Clearance, MODD1, Pivot Pump, Type 1 Diabetes, Type 2 Diabetes, Patch Pump, Healthcare Technology, SEC Filing, 10-K, Financial Reporting, Going Concern, Capital Raise, Biotechnology, Pharmaceuticals, Healthcare Industry, Regulatory Approval, Commercialization